TY - JOUR
T1 - Network Pharmacology Analysis of Bioactive Components and Mechanisms of Action of Qi Wei Wan Formula for Treating Non-Small Cell Lung Carcinoma
AU - Zhang, Minghe
AU - Wang, Ye
AU - Amin, Aftab
AU - Khan, Muhammad Ajmal
AU - Yu, Zhiling
AU - Liang, Chun
N1 - Funding Information:
This work was supported by the Guangzhou Innovation and Entrepreneurship Leading Team Project [202009020005] and the Science and Technology Innovation Bureau of Guangzhou Development District [CY2019-005].
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Science and Technology Innovation Bureau of Guangzhou Development District, the Guangzhou Innovation and Entrepreneurship Leading Team Project (grant number CY2019-005, 202009020005).
Publisher Copyright:
© The Author(s) 2022.
PY - 2022/10
Y1 - 2022/10
N2 - Astragali Radix (AR) and Schisandrae chinensis Fructus (SCF) have been used individually and in traditional Chinese medicine (TCM) formulas for treating non-small cell lung carcinoma (NSCLC). Qi Wei Wan (QWW), a 2-herb TCM formula composed of AR and SCF, is used to treat blood deficiency, fatigue, and metabolic abnormalities. We speculate that QWW may be more effective in treating NSCLC than AR or SCF alone. We identified 28 bioactive compounds in QWW and 322 targets of these compounds from databases. Network pharmacology analysis was used to identify 248 putative NSCLC-related gene targets of the bioactive compounds in QWW. Common target genes were analyzed to build protein–protein interaction networks. Implicated biological functions and pathways (p53, PI3K-Akt, etc) were identified by Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses. Molecular docking of core target proteins with the key active compounds was also performed. This study identified the potential gene targets and mechanisms involved in the anti-NSCLC effects of QWW.
AB - Astragali Radix (AR) and Schisandrae chinensis Fructus (SCF) have been used individually and in traditional Chinese medicine (TCM) formulas for treating non-small cell lung carcinoma (NSCLC). Qi Wei Wan (QWW), a 2-herb TCM formula composed of AR and SCF, is used to treat blood deficiency, fatigue, and metabolic abnormalities. We speculate that QWW may be more effective in treating NSCLC than AR or SCF alone. We identified 28 bioactive compounds in QWW and 322 targets of these compounds from databases. Network pharmacology analysis was used to identify 248 putative NSCLC-related gene targets of the bioactive compounds in QWW. Common target genes were analyzed to build protein–protein interaction networks. Implicated biological functions and pathways (p53, PI3K-Akt, etc) were identified by Kyoto Encyclopedia of Genes and Genomes and Gene Ontology analyses. Molecular docking of core target proteins with the key active compounds was also performed. This study identified the potential gene targets and mechanisms involved in the anti-NSCLC effects of QWW.
KW - Astragali Radix
KW - flavonoids
KW - lignans
KW - network pharmacology
KW - non-small cell lung carcinoma
KW - Schisandrae chinensis Fructus
KW - TCM
KW - terpenoids
UR - http://www.scopus.com/inward/record.url?scp=85139467691&partnerID=8YFLogxK
U2 - 10.1177/1934578X221120215
DO - 10.1177/1934578X221120215
M3 - Journal article
AN - SCOPUS:85139467691
SN - 1934-578X
VL - 17
JO - Natural Product Communications
JF - Natural Product Communications
IS - 10
ER -
